SG11201804587QA - Isoindole compounds - Google Patents

Isoindole compounds

Info

Publication number
SG11201804587QA
SG11201804587QA SG11201804587QA SG11201804587QA SG11201804587QA SG 11201804587Q A SG11201804587Q A SG 11201804587QA SG 11201804587Q A SG11201804587Q A SG 11201804587QA SG 11201804587Q A SG11201804587Q A SG 11201804587QA SG 11201804587Q A SG11201804587Q A SG 11201804587QA
Authority
SG
Singapore
Prior art keywords
international
astrazeneca
molndal
pct
compound
Prior art date
Application number
SG11201804587QA
Inventor
Sarah LEVER
Frank Narjes
Roine Olsson
Berg Stefan Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201804587QA publication Critical patent/SG11201804587QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

International Patent Classification: A61P 11/06 (2006.01) A61P 11/12 (2006.01) A61P 17/06 (2006.01) A61P 37/00 (2006.01) CO7D 407/06 (2006.01) CO7D 209/44 (2006.01) A61K 31/4035 (2006.01) A61P 1/04 (2006.01) A61P 1/18 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/EP2016/080885 (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/267391 15 December 2015 (15.12.2015) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: LEVER, Sarah; AstraZeneca, SE-431 83 Molndal (SE). NARJES, Frank; AstraZeneca, SE-431 83 Molndal (SE). OLSSON, Roble, Ingemar; AstraZeneca, SE-431 83 Molndal (SE). VON BERG, Stefan; As- traZeneca, SE-431 83 Molndal (SE). (74) Agent: ANDREW JAMES COOK; ASTRAZENECA INTELLECTUAL PROPERTY, Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 14 December 2016 (14.12.2016) English English Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: — with international search report (Art. 21(3)) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111111110111011111111111010111110111111111101010111111110111111111110111111 (43) International Publication Date 22 June 2017 (22.06.2017) (10) International Publication Number WO 2017/102784 Al WIPO I PCT (54) Title: ISOINDOLE COMPOUNDS (T) W O 20 17 / 10 27 8 4 Al (57) : The present specification provides a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof; a pro - cess for preparing such a compound; and to the use of such a compound in the treatment of an RORy and/or RORyt mediated disease state.
SG11201804587QA 2015-12-15 2016-12-14 Isoindole compounds SG11201804587QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267391P 2015-12-15 2015-12-15
PCT/EP2016/080885 WO2017102784A1 (en) 2015-12-15 2016-12-14 Isoindole compounds

Publications (1)

Publication Number Publication Date
SG11201804587QA true SG11201804587QA (en) 2018-06-28

Family

ID=57708552

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804587QA SG11201804587QA (en) 2015-12-15 2016-12-14 Isoindole compounds

Country Status (27)

Country Link
US (4) US10011566B2 (en)
EP (1) EP3390396B1 (en)
JP (1) JP6448867B2 (en)
KR (1) KR101947976B1 (en)
CN (1) CN109071516B (en)
AR (1) AR107054A1 (en)
AU (1) AU2016374294B2 (en)
BR (1) BR112018011851A2 (en)
CA (1) CA3007893A1 (en)
CL (1) CL2018001573A1 (en)
CO (1) CO2018005983A2 (en)
CR (1) CR20180328A (en)
DO (1) DOP2018000148A (en)
EA (1) EA034514B1 (en)
ES (1) ES2927631T3 (en)
IL (1) IL259818B (en)
MX (1) MX2018007296A (en)
MY (1) MY196276A (en)
NI (1) NI201800071A (en)
PE (1) PE20181319A1 (en)
PH (1) PH12018501237A1 (en)
SG (1) SG11201804587QA (en)
SV (1) SV2018005713A (en)
TN (1) TN2018000188A1 (en)
TW (1) TWI728017B (en)
WO (1) WO2017102784A1 (en)
ZA (1) ZA201804618B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034514B1 (en) 2015-12-15 2020-02-14 Астразенека Аб Isoindole compounds
CN110730780A (en) 2017-06-14 2020-01-24 阿斯利康(瑞典)有限公司 2, 3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
WO2020035557A1 (en) 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2020035556A1 (en) 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
TW202146389A (en) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 Biaryl compound capable of serving as ror[gamma] modulator
WO2021228217A1 (en) * 2020-05-15 2021-11-18 上海辉启生物医药科技有限公司 ANILINE COMPOUND USED AS RORγ REGULATOR
KR102422891B1 (en) 2022-01-26 2022-07-20 (주)셀시스템 Integrated solar hot water and battery charging device with AI-based priority control function and charging method using the same
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CN1298404A (en) 1998-02-25 2001-06-06 遗传研究所有限公司 Inhibitors of phospholipase A2
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
EP1212065A4 (en) 1999-07-08 2004-02-11 Tularik Inc Compositions and methods for raising hdl cholesterol levels
ES2252230T3 (en) 2000-05-11 2006-05-16 Bristol-Myers Squibb Company USEFUL TETRAHYDROISOQUINOLINE ANALOGS AS SECRETORS OF GROWTH HORMONE.
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
EP1341765A1 (en) 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
WO2002058690A2 (en) 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003082198A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Methods of treatment with lxr modulators
EP1501867A1 (en) 2002-04-29 2005-02-02 Novartis AG Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
WO2005009383A2 (en) 2003-07-22 2005-02-03 Glaxo Group Limited Methods of treatment with lxr agonists
EP1653938A2 (en) 2003-07-28 2006-05-10 Glaxo Group Limited Methods of treatment of inflammatory bowel disease with lxr agonists
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
WO2007055374A1 (en) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for osteoporosis
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
AR059826A1 (en) 2006-03-13 2008-04-30 Univ California UREA INHIBITORS CONFORMATIONALLY RESTRICTED OF SOLUBLE HYDROLASSE EPOXIDE
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
TW200812962A (en) 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
JP2009542803A (en) * 2006-07-12 2009-12-03 アストラゼネカ・アクチエボラーグ 3-oxoisoindoline-1-carboxamide derivatives as analgesics
CN101534820A (en) 2006-09-15 2009-09-16 细胞基因公司 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
JP4846769B2 (en) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 Pharmaceutical composition
JP4834699B2 (en) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 Pharmaceutical composition
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013100027A1 (en) 2011-12-28 2013-07-04 武田薬品工業株式会社 Heterocyclic compound
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
US9447069B2 (en) 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
WO2013166013A1 (en) 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
KR101936851B1 (en) * 2012-07-16 2019-01-11 한국과학기술연구원 Pyrazolopyridine or indazole derivatives as protein kinase inhibitors
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
WO2015002230A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Amide compound
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
WO2015035032A1 (en) 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
MY179106A (en) 2013-12-05 2020-10-28 Lead Pharma Holding Bv Ror gamma (rory) modulators
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
WO2015129853A1 (en) 2014-02-27 2015-09-03 東レ株式会社 Cyclic amine derivative and pharmaceutical use thereof
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
ME03513B (en) 2014-04-14 2020-04-20 Boehringer Ingelheim Int Compounds as modulators of ror gamma
PE20161399A1 (en) 2014-04-16 2017-01-14 Glenmark Phamaceuticals S A ARIL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS
US9365520B2 (en) 2014-07-01 2016-06-14 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016020295A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MA40759A (en) 2014-09-26 2017-08-01 Pfizer PYRROLOPYRIDINE-SUBSTITUTED BY METHYL AND TRIFLUOROMETHYL RORC2 MODULATORS AND THEIR METHODS OF USE
WO2016061160A1 (en) 2014-10-14 2016-04-21 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
JP2017538676A (en) 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス Small molecule inhibitors of mitochondrial permeability transition pore (mtPTP)
WO2016176399A1 (en) 2015-04-28 2016-11-03 Stc.Unm Compositions and methods for treatment of pulmonary hypertension
EP3845526A1 (en) 2015-05-15 2021-07-07 Aurigene Discovery Technologies Limited Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (en) 2015-07-10 2017-01-19 塩野義製薬株式会社 COMPOUNDS HAVING RORγt INHIBITORY EFFECTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ES2856931T3 (en) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc ROR-gamma modulators
EP3356366B1 (en) 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
EA034514B1 (en) 2015-12-15 2020-02-14 Астразенека Аб Isoindole compounds

Also Published As

Publication number Publication date
AU2016374294A1 (en) 2018-07-19
TW201738210A (en) 2017-11-01
CA3007893A1 (en) 2017-06-22
IL259818A (en) 2018-07-31
CL2018001573A1 (en) 2018-07-27
BR112018011851A2 (en) 2018-12-04
CO2018005983A2 (en) 2018-06-20
EP3390396A1 (en) 2018-10-24
US20170166527A1 (en) 2017-06-15
KR101947976B1 (en) 2019-02-13
US20190084934A1 (en) 2019-03-21
EP3390396B1 (en) 2022-07-06
NI201800071A (en) 2018-10-18
JP6448867B2 (en) 2019-01-09
AR107054A1 (en) 2018-03-14
TWI728017B (en) 2021-05-21
US20200181084A1 (en) 2020-06-11
CN109071516B (en) 2021-08-31
KR20180086269A (en) 2018-07-30
US10011566B2 (en) 2018-07-03
CN109071516A (en) 2018-12-21
SV2018005713A (en) 2018-08-08
US11453644B1 (en) 2022-09-27
EA034514B1 (en) 2020-02-14
ZA201804618B (en) 2020-09-30
MX2018007296A (en) 2019-01-10
EA201891342A1 (en) 2019-01-31
US10988445B2 (en) 2021-04-27
PH12018501237A1 (en) 2019-02-18
US10526286B2 (en) 2020-01-07
JP2018537485A (en) 2018-12-20
TN2018000188A1 (en) 2019-10-04
WO2017102784A1 (en) 2017-06-22
CR20180328A (en) 2018-08-09
PE20181319A1 (en) 2018-08-14
DOP2018000148A (en) 2018-07-15
ES2927631T3 (en) 2022-11-08
AU2016374294B2 (en) 2019-06-27
IL259818B (en) 2021-05-31
MY196276A (en) 2023-03-24
WO2017102784A9 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
SG11201804587QA (en) Isoindole compounds
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201808108XA (en) Synthesis of indazoles
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201808686VA (en) Synthesis of indazoles
SG11201805001UA (en) Method of treating influenza a
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201805755SA (en) Methods of administering hepcidin
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201908513RA (en) Peptides for treatment of diabetes